51�ԹϹ��

Press
Releases

51�ԹϹ�� Publishes two New Papers Highlighting the Potential of mRNA Vaccines to Outpace Evolving Viruses like COVID-19

Written on January 13, 2025

51�ԹϹ�� and Ontario Institute for Cancer Research (OICR) partnering to discover and develop mRNA therapeutics

Written on May 23, 2024

51�ԹϹ�� Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development

Written on June 06, 2023

51�ԹϹ�� Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

51�ԹϹ�� Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022 World Vaccine & Immunotherapy Congress

51�ԹϹ�� Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults

51�ԹϹ�� Signs Licensing Agreement with SickKids for Immunotargeting Technology

BioAlberta Recognizes Alberta Innovators and Entrepreneurs at 2021 Achievement Awards Ceremony, Sir Michael Houghton Inducted Into Alberta Bioindustry Hall of Fame

51�ԹϹ�� and Everest Medicines announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program

51�ԹϹ�� announces $ 2.118 Million USD in funding to support process development and validation of the PTX-COVID19-B program, which targets high quality mRNA COVID-19 vaccine to low-to middle-income countries at affordable prices.

51�ԹϹ�� Announces Donna T. Ward, Ph.D., J.D. appointment to Board of Directors

Everest Medicines and 51�ԹϹ�� Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

51�ԹϹ�� Submits Clinical Trial Application (CTA) to Health Canada for its mRNA COVID Vaccine

51�ԹϹ�� COVID-19 Vaccine Receives Health Canada Authorization to Begin Clinical Trials

51�ԹϹ�� Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B)

Northern RNA and 51�ԹϹ�� Announce Multi-year Agreement to Provide Essential Raw Materials and GMP Manufacturing in Support of 51�ԹϹ�� mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With 51�ԹϹ�� for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

51�ԹϹ�� Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta

51�ԹϹ�� Enters into Comprehensive Agreements with Everest Medicines to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Emerging Markets in Asia

51�ԹϹ�� Announces First Subject Has Been Dosed in Covid-19 Vaccine Trial

51�ԹϹ�� Holdings Inc. Of Canada and Biological E. Limited of India Announce the Execution of a Term Sheet for the Licensing and Collaboration of mRNA Vaccine

51�ԹϹ�� Announces Very Favorable Interim Phase 1 Trial Data for PTX-COVID19-B, its mRNA Vaccine Against COVID-19